Nifty
:
26068.15
Sensex
:
85231.92
-124.00 (-0.47%)
-400.76 (-0.47%)
Nifty
Sensex
:
:
26068.15
85231.92
-124.00 (-0.47%)
-400.76 (-0.47%)

Shilpa Medicare Ltd.

Pharmaceuticals & Drugs - Global

Rating :
48/99

BSE: 530549 | NSE: SHILPAMED

NSE BSE
350.60
21-Nov-2025
  • Open
  • High
  • Low
  • Previous Close
  •  356.05
  •  356.2
  •  349.1
  •  356.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  130310
  •  45893943.2
  •  500
  •  277.5

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 6,861.01
  • 49.99
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 7,430.30
  • 0.14%
  • 2.80

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 44.23%
  • 10.17%
  • 23.35%
  • FII
  • DII
  • Others
  • 10.92%
  • 6.24%
  • 5.09%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.03
  • 7.38
  • 7.00

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.63
  • 12.10
  • 28.05

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -3.33
  • -11.93
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 31.35
  • 72.39
  • 77.46

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 2.57
  • 2.40
  • 2.39

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.31
  • 23.63
  • 23.99

Earnings Forecasts:

(Updated: 22-11-2025)
Description
2024
2025
2026
2027
Adj EPS
4
11.55
17.85
30
P/E Ratio
87.65
30.35
19.64
11.69
Revenue
1286.41
1574.8
1872.75
2438.3
EBITDA
317.05
487.45
633.65
853.1
Net Income
78.29
229.55
349.3
586.7
ROA
2.45
P/B Ratio
2.89
2.64
2.33
1.92
ROE
3.75
8.85
12.5
17.9
FCFF
-180.13
148.88
271.1
378.7
FCFF Yield
-2.36
1.95
3.55
4.95
Net Debt
561.78
BVPS
121.29
132.68
150.23
182.15

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Net Sales
369.97
343.80
7.61%
321.46
292.51
9.90%
330.81
291.69
13.41%
319.32
286.76
11.35%
Expenses
261.69
257.79
1.51%
229.82
218.99
4.95%
254.04
221.63
14.62%
238.62
220.53
8.20%
EBITDA
108.28
86.00
25.91%
91.64
73.52
24.65%
76.77
70.06
9.58%
80.69
66.23
21.83%
EBIDTM
29.27%
25.02%
28.51%
25.13%
23.21%
24.02%
25.27%
23.09%
Other Income
1.75
4.99
-64.93%
6.38
9.52
-32.98%
7.57
2.49
204.02%
1.13
1.94
-41.75%
Interest
15.67
25.55
-38.67%
18.78
23.74
-20.89%
14.49
24.20
-40.12%
11.75
26.22
-55.19%
Depreciation
29.82
28.28
5.45%
28.92
27.11
6.68%
28.79
26.63
8.11%
28.81
26.71
7.86%
PBT
64.54
37.16
73.68%
50.31
32.20
56.24%
12.97
27.85
-53.43%
41.27
15.23
170.98%
Tax
20.36
18.83
8.13%
2.69
14.62
-81.60%
0.77
3.21
-76.01%
9.83
9.46
3.91%
PAT
44.18
18.33
141.03%
47.62
17.58
170.88%
12.21
24.64
-50.45%
31.44
5.77
444.89%
PATM
11.94%
5.33%
14.81%
6.01%
3.69%
8.45%
9.85%
2.01%
EPS
2.25
0.92
144.57%
2.40
0.72
233.33%
0.74
1.41
-47.52%
1.63
0.26
526.92%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
1,341.56
1,286.41
1,151.60
1,050.11
1,145.52
901.13
907.91
733.39
788.83
779.16
716.43
Net Sales Growth
10.44%
11.71%
9.66%
-8.33%
27.12%
-0.75%
23.80%
-7.03%
1.24%
8.76%
 
Cost Of Goods Sold
380.59
397.67
394.23
416.04
383.22
270.73
277.73
257.03
355.87
371.81
366.19
Gross Profit
960.97
888.74
757.37
634.07
762.30
630.40
630.18
476.36
432.95
407.36
350.25
GP Margin
71.63%
69.09%
65.77%
60.38%
66.55%
69.96%
69.41%
64.95%
54.89%
52.28%
48.89%
Total Expenditure
984.17
982.48
916.10
961.84
948.32
729.43
693.39
579.39
637.60
617.55
556.44
Power & Fuel Cost
-
53.74
52.41
56.79
52.43
40.25
38.76
33.57
28.86
26.30
21.90
% Of Sales
-
4.18%
4.55%
5.41%
4.58%
4.47%
4.27%
4.58%
3.66%
3.38%
3.06%
Employee Cost
-
292.71
281.39
286.39
264.49
235.31
196.59
176.40
149.35
127.87
90.09
% Of Sales
-
22.75%
24.43%
27.27%
23.09%
26.11%
21.65%
24.05%
18.93%
16.41%
12.57%
Manufacturing Exp.
-
122.29
95.70
110.32
124.11
91.29
79.19
61.23
59.96
52.55
45.35
% Of Sales
-
9.51%
8.31%
10.51%
10.83%
10.13%
8.72%
8.35%
7.60%
6.74%
6.33%
General & Admin Exp.
-
59.02
43.99
46.86
71.58
47.71
70.26
27.20
22.50
16.95
14.11
% Of Sales
-
4.59%
3.82%
4.46%
6.25%
5.29%
7.74%
3.71%
2.85%
2.18%
1.97%
Selling & Distn. Exp.
-
26.53
21.42
18.56
18.02
18.63
10.40
6.72
6.37
4.75
7.27
% Of Sales
-
2.06%
1.86%
1.77%
1.57%
2.07%
1.15%
0.92%
0.81%
0.61%
1.01%
Miscellaneous Exp.
-
30.52
26.96
26.89
34.49
25.51
20.47
17.23
14.68
17.32
7.27
% Of Sales
-
2.37%
2.34%
2.56%
3.01%
2.83%
2.25%
2.35%
1.86%
2.22%
1.61%
EBITDA
357.38
303.93
235.50
88.27
197.20
171.70
214.52
154.00
151.23
161.61
159.99
EBITDA Margin
26.64%
23.63%
20.45%
8.41%
17.21%
19.05%
23.63%
21.00%
19.17%
20.74%
22.33%
Other Income
16.83
36.27
17.16
31.41
20.90
40.09
22.22
15.56
32.62
29.34
11.36
Interest
60.69
75.53
91.80
58.65
41.17
21.87
4.56
3.68
2.66
3.13
3.93
Depreciation
116.34
112.99
107.87
95.50
79.80
53.98
43.78
42.06
37.22
30.64
23.14
PBT
169.09
151.68
52.99
-34.47
97.13
135.95
188.40
123.82
143.96
157.17
144.28
Tax
33.65
44.04
22.39
-7.36
41.68
48.85
33.49
26.18
33.91
42.04
35.62
Tax Rate
19.90%
35.63%
37.87%
21.35%
39.35%
24.82%
17.78%
18.22%
23.56%
27.54%
25.11%
PAT
135.45
78.30
31.88
-32.48
60.66
147.78
156.50
120.28
112.43
113.71
109.84
PAT before Minority Interest
135.45
78.30
31.96
-30.92
60.58
146.20
154.91
117.52
110.05
110.59
106.24
Minority Interest
0.00
0.00
-0.08
-1.56
0.08
1.58
1.59
2.76
2.38
3.12
3.60
PAT Margin
10.10%
6.09%
2.77%
-3.09%
5.30%
16.40%
17.24%
16.40%
14.25%
14.59%
15.33%
PAT Growth
104.24%
145.61%
-
-
-58.95%
-5.57%
30.11%
6.98%
-1.13%
3.52%
 
EPS
13.85
8.01
3.26
-3.32
6.20
15.11
16.00
12.30
11.50
11.63
11.23

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
2,372.24
1,808.69
1,783.28
1,822.19
1,478.67
1,329.36
1,197.58
1,085.03
986.90
639.26
Share Capital
9.78
8.68
8.68
8.68
8.15
8.15
8.15
8.15
8.01
7.71
Total Reserves
2,362.46
1,800.01
1,774.60
1,813.51
1,470.51
1,321.21
1,189.43
1,076.88
978.88
631.55
Non-Current Liabilities
259.81
589.44
345.12
452.82
561.37
256.94
166.62
153.48
251.26
67.23
Secured Loans
231.96
560.16
242.92
353.49
473.87
164.48
80.39
67.09
141.20
0.03
Unsecured Loans
0.00
0.00
45.90
0.11
0.35
0.53
0.70
1.03
1.30
0.00
Long Term Provisions
25.54
22.43
17.65
19.08
15.48
26.17
21.77
20.32
16.89
13.96
Current Liabilities
674.23
693.59
784.45
611.54
543.29
410.82
253.44
265.84
236.90
222.07
Trade Payables
95.38
174.15
142.80
146.04
67.25
92.55
80.72
103.74
111.86
106.48
Other Current Liabilities
222.13
138.05
276.56
240.13
219.33
142.10
81.62
59.59
28.03
36.49
Short Term Borrowings
306.81
360.73
344.17
202.90
243.40
165.27
86.58
98.12
92.41
74.10
Short Term Provisions
49.91
20.66
20.92
22.46
13.31
10.89
4.52
4.39
4.60
5.00
Total Liabilities
3,297.74
3,082.98
2,903.93
2,875.50
2,572.16
1,989.21
1,610.02
1,499.13
1,472.22
930.89
Net Block
1,417.84
1,384.86
1,368.33
1,341.84
1,110.53
650.44
558.01
534.20
491.93
393.41
Gross Block
2,075.99
1,946.75
1,846.68
1,727.09
1,421.10
986.42
853.16
793.24
704.89
582.20
Accumulated Depreciation
658.15
561.89
478.35
385.25
310.57
335.98
295.15
259.04
212.96
188.79
Non Current Assets
2,312.07
2,206.74
2,134.37
1,988.30
1,729.60
1,365.35
1,064.96
827.16
742.33
576.68
Capital Work in Progress
821.77
718.78
655.33
506.18
541.29
666.25
429.12
209.85
140.51
91.90
Non Current Investment
34.54
39.91
42.66
34.23
21.22
10.45
2.25
20.79
27.99
34.15
Long Term Loans & Adv.
36.55
53.32
56.53
93.90
43.10
32.42
48.75
37.47
77.09
51.86
Other Non Current Assets
1.37
9.87
11.52
12.15
13.46
5.78
26.84
24.86
4.80
5.36
Current Assets
985.67
876.24
769.55
887.19
818.99
623.85
545.06
671.97
729.88
354.21
Current Investments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
119.54
224.62
59.63
Inventories
347.93
344.93
319.82
355.24
316.84
226.43
187.67
188.71
190.00
134.23
Sundry Debtors
440.84
392.05
324.35
386.33
217.50
246.79
203.73
220.27
170.93
125.43
Cash & Bank
28.52
31.77
21.56
34.11
123.11
44.56
94.54
73.83
100.39
11.03
Other Current Assets
168.38
16.28
15.53
9.36
161.54
106.06
59.12
69.62
43.95
23.90
Short Term Loans & Adv.
150.79
91.22
88.29
102.16
62.81
29.25
14.08
43.54
21.95
8.90
Net Current Assets
311.44
182.65
-14.89
275.66
275.69
213.04
291.62
406.13
492.98
132.14
Total Assets
3,297.74
3,082.98
2,903.92
2,875.49
2,548.59
1,989.20
1,610.02
1,499.13
1,472.21
930.89

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
132.18
136.67
179.92
105.13
46.93
124.38
146.78
44.92
37.48
128.70
PBT
122.33
54.34
-38.28
102.26
196.79
188.40
143.70
136.77
146.49
140.36
Adjustment
195.04
221.44
147.81
109.34
4.03
41.32
20.44
18.83
17.19
20.61
Changes in Working Capital
-138.18
-97.92
102.77
-71.99
-106.29
-63.15
18.71
-69.66
-92.61
-2.70
Cash after chg. in Working capital
179.20
177.86
212.30
139.62
94.53
166.57
182.85
85.94
71.08
158.27
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-47.02
-41.19
-32.37
-34.48
-47.60
-42.20
-36.07
-41.02
-33.60
-29.56
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-199.08
-166.58
-232.61
-285.50
-404.28
-289.52
-196.16
-8.76
-262.23
-109.20
Net Fixed Assets
-78.45
-17.18
-22.18
384.16
-272.02
-4.28
-256.96
-136.75
-172.23
-92.14
Net Investments
-1,033.05
-2.53
-6.42
-18.18
-125.84
-4.44
141.85
95.51
-172.72
-14.09
Others
912.42
-146.87
-204.01
-651.48
-6.42
-280.80
-81.05
32.48
82.72
-2.97
Cash from Financing Activity
62.65
46.77
45.80
82.86
436.37
175.50
10.06
-60.91
312.70
-19.65
Net Cash Inflow / Outflow
-4.25
16.86
-6.89
-97.51
79.03
10.36
-39.32
-24.75
87.95
-0.15
Opening Cash & Equivalents
31.76
19.07
25.62
122.85
44.31
34.13
73.83
99.97
7.05
3.61
Closing Cash & Equivalent
28.52
31.76
19.07
25.34
123.34
44.31
34.36
73.83
99.97
6.43

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
121.29
104.19
205.44
209.93
181.37
163.06
146.89
133.09
123.17
82.91
ROA
2.45%
1.07%
-1.07%
2.20%
6.33%
8.61%
7.56%
7.41%
9.20%
11.58%
ROE
3.75%
1.78%
-1.71%
3.67%
10.41%
12.26%
10.30%
10.62%
13.60%
17.92%
ROCE
6.94%
5.49%
0.80%
5.94%
10.73%
12.41%
11.05%
11.71%
15.91%
19.90%
Fixed Asset Turnover
0.64
0.61
0.59
0.73
0.75
0.99
0.89
1.06
1.22
1.36
Receivable days
118.16
113.53
123.51
98.75
94.03
90.56
105.51
90.20
69.00
52.26
Inventory Days
98.29
105.35
117.32
109.68
110.03
83.24
93.66
87.32
75.49
66.97
Payable days
123.69
146.72
126.70
106.00
107.72
47.69
58.00
61.51
60.89
60.10
Cash Conversion Cycle
92.76
72.15
114.12
102.43
96.33
126.11
141.17
116.00
83.61
59.13
Total Debt/Equity
0.25
0.52
0.45
0.37
0.57
0.29
0.16
0.18
0.24
0.14
Interest Cover
2.62
1.59
0.35
3.48
9.92
42.34
40.09
55.10
49.69
37.07

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • USFDA completes inspection at Shilpa Medicare’s Telangana Unit
    22nd Nov 2025, 15:59 PM

    The ten day inspection ended with the issuance of FDA Form 483 with eight inspectional observations none of which has been categorized as a repeat observation

    Read More
  • Shilpa Medicare - Quarterly Results
    14th Nov 2025, 00:00 AM

    Read More
  • Shilpa Medicare reports positive Phase 3 results for OERIS
    10th Nov 2025, 15:51 PM

    OERIS (Ondansetron Extended-Release Injection) is an innovative formulation designed to improve prophylaxis of chemotherapy-induced nausea and vomiting (CINV)

    Read More
  • Shilpa Medicare gets initial authorization for Rivaroxaban Orodispersible Films
    23rd Sep 2025, 11:57 AM

    This approval has come from the Company’s finished dosage form manufacturing facility, Shilpa Medicare, Unit VI, located at Dabaspet, Bengaluru, Karnataka

    Read More
  • Shilpa Medicare’s arm to form new joint venture company in Saudi Arabia
    28th Aug 2025, 11:11 AM

    The new limited liability company will be majority owned by PPI (70%), with Koanna holding a 30% stake

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.